Jan 09, 2023 8:00am EST Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Dec 21, 2022 8:00am EST Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation
Nov 14, 2022 4:05pm EST Achieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update
Nov 08, 2022 8:00am EST Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial
Oct 31, 2022 8:00am EDT Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022
Sep 27, 2022 8:00am EDT Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Aug 11, 2022 4:05pm EDT Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update
Jul 28, 2022 8:00am EDT Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022